MedVax Technologies, Inc. is a private biopharmaceutical company developing and commercializing immunotherapeutic treatments. MedVax’s portfolio includes an autologous Adenovirus P53 dendritic cell vaccine in two FDA Phase II clinical trials, in Small Cell Lung Cancer, and Breast Cancer. Medvax also has a chimeric HER2 Peptide vaccine that is concluding a 2nd Phase I trial, and preparing for a phase II trial.